A comparison of the performance of two modern multidose dry powder asthma inhalers

Respiratory Medicine

Volumn 92, Issue 1, 1998, Pages 105-110

  Hill, L S ^a   Slater, A L ^b  

^a WARWICK HOSPITAL   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; SALBUTAMOL;

ARTICLE; ASTHMA; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; POWDER INHALER; PRIORITY JOURNAL;

EID: 0031939585     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90040-3     Document Type: Article

References (17)

1. Woodcock A. CFCs and inhalers. Lancet 1994; 334: 182-183.
2. Bisgaard H. Drug delivery from Inhaler devices. BMJ 1996; 313: 895-896.
3. Lipworth BJ. New perspectives on inhaled drug therapy and systemic bioactivity. Thorax 1995; 50: 105-110.
4. Newman SP, Pavia D, Moren F et al. Deposition of pressurised aerosols in the human respiratory tract. Thorax 1981; 36: 52-55.
5. Rogers DF, Ganderton D. Determining the equivalence of inhaled medications. Respir Med 1995; 89: 253-261.
6. Persson G, Wirén JE. The bronchodilator response from inhaled terbutaline is influenced by the mass of small particles: a study on a dry powder inhaler [turbohaler]. Eur Respir J 1989; 2: 253-256.
7. Byron PR, Hindle M. Dose emissions from marketed dry powder inhalers. Int J Pharmaceutics 1995; 116: 169-177.
8. Meakin BJ, Cainey JM, Woodcock PM. Drug delivery characteristics of Bricanyl Turbuhaler™ dry powder inhalers. Int J Pharmaceutics 1995; 119: 91-102.
9. Hindle M, Jashani RN, Byron PR. Dose emissions from marketed inhalers: Influence of flow, volume and environment. Respiratory Drug Delivery IV 1994. Buffalo Grove, IL: Interpharm Press, pp. 137-142.
10. Ifversen M, Bisgaard H, Klug B et al. Inspiratory flow rate through the Diskus™/Accuhaler™ inhaler and Turbuhaler™ inhaler in children with asthma. ERS Annual Congress 1995; P2107.
11. Olsson B, Aiche JM, Bull H et al. The use of inertial impactors to measure fine particle dose generated by inhalers. Pharmoeuropa 1996; 8: 291-298.
12. de Boer AH, Lerk CF. Effect of inspiratory flow rate on in-vitro drug delivery from breath actuated dry powder inhalers. ERS Annual Congress 1995; P2106.
13. Bisgaard H. Use of Budesonide Turbuhaler™ in young children suspected of asthma. Eur Respir J 1994; 7: 740-742.
14. De Boer AH, Hagedoorn P, Gjaltema D. Effect of flow increase rate [FIR] on fine particle output from budesonide Turbuhaler. Eur Respir J 1996; 9: S23 2065.
15. Olsson B, Asking L. Critical aspects of the function of inspiratory driven inhalers. J Aerosol Med 1994; 7: S1: S43-S47.
16. Hindle M, Byron PR, Miller N. Cascade impaction methods for dry powder inhalers using the high flow rate Marple-Miller Impactor. Int J Pharm 1996; 134: 137-146.
17. Bryon PR, Kelly EL, Kontny et al. Recommendations of the USP advisory panel on aerosols. Pharm Forum 1994; 20: 7477-7505.